← Browse by Condition
Medical Condition

myeloproliferative neoplasm

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for myeloproliferative neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myeloproliferative neoplasm Clinical Trials

How many clinical trials are currently recruiting for myeloproliferative neoplasm?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for myeloproliferative neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myeloproliferative neoplasm?
myeloproliferative neoplasm research spans Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myeloproliferative neoplasm clinical trial?
Eligibility criteria for myeloproliferative neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
4
Top Sponsors
Masonic Cancer Center, University of Minnesota 1 trial
The University of Hong Kong 1 trial
University Health Network, Toronto 1 trial
University of Miami 1 trial
The First Affiliated Hospital of Soochow University 1 trial

Recruiting Clinical Trials

NCT05805605 Phase 2
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT05882773
Recruiting
Asian Myeloproliferative Neoplasm (MPN) Registry
Enrollment
1,000 pts
Location
Hong Kong
Sponsor
The University of Hong Kong
View Trial →
NCT05074355 Phase 2
Recruiting
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Enrollment
40 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT05745285
Recruiting
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Enrollment
400 pts
Location
United States
Sponsor
University of Miami
View Trial →
NCT05521204 Phase 2
Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06059391 Phase 2
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment
216 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT05714592
Recruiting
Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
Enrollment
300 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
View Trial →

Related Conditions

myelodysplastic syndromes (2) myelofibrosis (2) acute myelogenous leukemia (1) acute lymphocytic leukemia (1) biphenotypic acute leukemia (1) undifferentiated leukemia (1) prolymphocytic leukemia (1) chronic myelogenous leukemia (1) plasma cell leukemia (1) leukemia myeloid (1) myelodysplastic syndrome with excess blasts 1 (1) burkitt lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology